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We recently reported that partially purified native interferon-7 (nlFNT) and 
pure recombinant interferon-3' (rIFN3") induced human macrophages to secrete 
large amounts of reactive oxygen intermediates when appropriately triggered, 
and  to  kill  the  intracellular  protozoal  pathogens  Toxoplasma  gondii  (1)  and 
Leishmania  donovani  (2).  Taking these properties to define macrophage activa- 
tion, all detectable macrophage-activating factor (MAF) in the supernatant of 
mitogen- or antigen-stimulated blood mononuclear cells was eliminated by anti- 
IFN7 monoclonal antibody (1, 2). It thus appeared that IFN3, was necessary and 
sufficient for macrophage activation by these supernatants. However, additional 
studies are needed to learn whether other cytokines may also have MAF activity. 
The proliferative, endocytic, secretory, locomotive, and cytotoxic properties 
of macrophages can be influenced by IFNa (3, 4), IFN/3 (4-6), colony stimulating 
factor  type  1  (CSF-1)  (7-9),  colony stimulating factor  for  granulocytes and 
macrophages (GM-CSF) (10,  11), pluripotent colony stimulating factor (p-CSF), 1 
and migration inhibitory factor (MIF) (12).  Also worthy of study is interleukin 2 
(IL-2),  the  only secretory  product  of the  T  cell  other  than  IFNy  currently 
available as the pure product of a cloned gene (13),  and tumor necrosis factor 
(TNF) (14),  whose potential for macrophage activation has not previously been 
examined. We  studied highly purified preparations of each  of the  foregoing. 
Only IFN7  enhanced both  the H202 secretion and antitoxoplasma activity of 
human macrophages. 
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TABLE  I 
Cytokines Used in This Study 
601 
Cytokine  Mr  Specific activity*  Purity  Source 
rlFN-r 
nlFNa 
rlFNaA 
rlFNaD 
rlFNI3 
CSF-1 
GM-CSF 
p-CSF 
MIF 
34,292  2.6 + 0.4 X 10  a*  Pure 
17,800-20,000  1.4 X 10  ~  Pure 
19,219  2 X 10  s  Pure 
19,392  2 X l0  s  Pure 
19,987  2 ×  l0  s  Pure 
4 X 10  e  ~5% 
3.8 ×  103  Partial 
1.5 ×  l0  s  Pure 
Note  I  Note  I 
TNF  106  Partial 
niL-2  7 ×  104  Partial 
rl L-2  15,421  106  Pure 
Genentech,  So. San Francisco, CA 
Leukocytes induced  with Sendai virus. 
Affinity purified! 
Hoffman-La Roche, Nutley,  NJ (17) 
Hoffman-La Roche (17) 
Hoffman-La Roche (17) 
Human urine, purified as in reference 
20 
Culture supernatant of T5637 bladder 
carcinoma cell line (footnote 1) 
As above, purified by DE52, AcA gel 
filtration,  and reverse phase HPLC 
T-T hybridoma concanavalin-stimulated 
supernate purified by salt fractiona- 
tion, phenyl Sepharose chromatogra- 
phy, and ion exchange HPLC 
Epstein-Barr virus-transformed B cell 
line supernate purified by sequential 
column chromatography (14) 
Genzyme, Inc., Norwalk, CT 
Biogen, Cambridge,  MA 
* U/mg protein. For IFN, international  antiviral  units.  For other cytokines, units of bioactivity as defined  in the 
cited references. 
* Based on antiviral assays performed by BYR as described  (1) and protein measurements by the method of Lowry 
et al. (15) using a bovine serum albumin standard.  Mean +- SEM for 3 separate lots, including  1 from Biogen 
that was used in 1 experiment with equivalent  results. 
g Using the monoclonal antibody described  in reference 16. Contains a mixture of subtypes. 
I Purified  ~100-fold  from the serum-free starting material.  Negative  for endotoxin by the limulus amebocyte 
lysate assay. IFN3' not detectable. 
Materials and Methods 
Human monocyte-derived macrophages were assayed for H20~ release, adherent cell 
protein, and antitoxoplasma activity as described  (1), except that the number of mono- 
nuclear cells plated ranged up to 2 × 106 and in many experiments, the volume of culture 
medium was increased  to 0.5  ml/well after the first day. The test  media described  in 
Table I were added on day 4, 5, or 6 and H202 release tested 3 d later. 
Results 
H202-Releasing Capacity,  Cell Shape, and Adherent Cell Protein.  Fig. 1 compares 
the  ability  of  11  cytokines to  enhance  the  oxidative  metabolism  of human 
monocyte-derived macrophages, rIFN% included as a positive control in each 
experiment, elevated macrophage H~O2-releasing capacity an average of eight- 
fold above that of cells cultured in medium alone. 50% of  the maximal stimulation 
required ~1  ×  10 -~2 M rIFN3, (~0.1  U/ml). The non-~, IFNs were tested over a 
105-fold  range  of concentrations,  up  to  104  antiviral  U/ml.  Pure  nIFNa  (a 
mixture of subtypes) did not enhance H202  release. In contrast to rIFN% nIFNa 
at > 1,000 U/ml decreased cell spreading and the amount of protein adherent to 
the  coverslips  (Table  II),  suggesting toxicity.  Results were  similar  with  pure 
rIFNotA, rIFNaD, and rIFNI3, except that rIFNaD had less effect on cell protein 
and no effect on cell shape. 
Partially purified CSF-1 and GM-CSF did not enhance H~O2 release. However, 
these preparations did interact with the macrophages, as evidenced by marked 
spreading of the cells and an increase in the adherent cell protein by a factor of 
1.25 _4- 0.48 (n -- 3) for CSF-1  (8) and 2.23 +  0.29 (n =  5) for GM-CSF. When 602  NATHAN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE  1.  H20~ release by phorbol myristate acetate-challenged  human macrophages after 
3  d  in  the indicated  cytokines.  Means __+ SEM  for the number of experiments noted above 
each point, each in triplicate with cells from a  different donor. A  unit of MIF is the amount 
in the active chromatographic fractions derived from  1 ml of starting material. 
added from day 5 or 6  of culture, pure p-CSF affected neither H202 release, cell 
shape, nor adherent  cell protein (the latter was 0.97  _+ 0.11  times the control, n 
=  3).  TNF  was  similarly  without  effect.  MIF-rich  fractions  increased  H202- 
releasing  capacity  approximately  fourfold  above  the  control.  Spreading  and 
adherent  cell  protein  also  tended  to  increase,  the  latter  by  a  factor  of  1.28  + 
0.20  (n  =  5).  rIL-2  enhanced  H202-releasing  capacity  slightly  at  104 U/ml,  but NATHAN  ET  AL.  BRIEF  DEFINITIVE  REPORT  603 
TABLE  II 
Effect of lFN% IFNa, IFN[3, and IL-2 on Adherent Cell Protein 
Adherent cell protein (% of control)* 
Test agent 
100'  1,000'  10,000' 
rlFN3,  125 4- 26 (8)  i  110 4- 20 (8)  Not done 
nIFNa  116 4- 33 (8)  84 4- 12 (8)  49 4- 5 (5) 
rlFNaA  77 4- 22 (4)  83 4- 21  (3)  63 4- 14 (4) 
rlFNaD  64 4- 3 (3)  96 4- 36 (3)  75 4- 30 (3) 
rlFN/~  86 4- 22 (5)  56 4- 18 (5)  46 4- 7 (5) 
rIL-2  88 4- 9 (3)  99 4- 13 (4)  85 4- 13 (2) 
* Control values (cell protein on saline-rinsed coverslips after incubation in medium 
alone) averaged 23.9 4- 6.6 ~g (13 experiments). 
* U/ml. 
! Mean 4- SEM for the number of experiments in parentheses, each in triplicate. 
TABLE  III 
Comparison of lFN7 with Other Cytokines  for Induction of 
Antitoxoplasma  Activity in Human Macrophages 
Agent*  U/ml  % Toxoplasmas killed  No. toxoplasmas/ 
at 4-6 h  vacuole at 20 h 
Medium  --  3.3 +  1.6 (7)*  6.1  4- 0.3 (9) 
rlFN7  100-300  42.9 4- 4.3 (7)  1.9 4- 0.1 (10) 
nIFNa  300-500 a  0.0 4- 0.0 (2)  5.2 4- 0.2 (2) 
rIFNaA  300-500 °  1.0 4- 0.7 (2)  5.8 4- 0.2 (2) 
rIFNaD  300-500 !  0.8 4- 0.7 (4)  5.1 4- 0.3 (5) 
rlFNB  300-500 !  0.0 4- 0.0 (3)  5.0 4- 0.4 (4) 
CSF-1  500  9.0 4- 4.2 (3)  5.4 4- 0.5 (3) 
GM-CSF  500  2.8 4- 1.9 (4)  6.1 4- 0.3 (4) 
MIF  1-301  7.2 4- 3.0 (6)  5.9 4- 0.6 (6) 
niL-2  10-100  5.0 4- 5.0 (2)  4,6 4- 0.4 (2) 
rlL-2  10-100  5.5 4- 3.3 (4)  4.8 4- 0.3 (4) 
* Macrophages were incubated  with the indicated  cytokines for 3  d  before being 
washed and challenged with toxoplasmas. The course of infection was followed in 
control medium for the next 20 h. 
* Mean 4- SEM for the number of experiments in parentheses, each in duplicate, 
J Higher concentrations were not tested because rounding up of the macrophages 
interfered with counting intracellular organisms. 
I As defined in the legend to Fig.  1. 
this effect was eliminated by the addition of monoclonal antibody against IFNT. 
Antitoxoplasma  Activity.  Under  the  conditions  tested,  none  of the  agents 
except rIFN7 conferred on macrophages the ability to kill T. gondii or to inhibit 
its intracellular replication (Table III). 
Discussion 
Therapy is now feasible with purified products of cloned genes. This heightens 
interest in the identification of cytokines that augment the antimicrobial activity 
of host cells.  Recent studies establish  that  IFN7  promotes host cell-mediated 
inhibition of a variety of nonviral pathogens, such as toxoplasma (1,  19),  leish- 
mania (2), chlamydia (20), rickettsia (21), and malaria. 2 However, it is not clear 
whether other cytokines can also enhance the nonviral antimicrobial activity of 
human macrophages or its biochemical correlate, their capacity to secrete reactive 
oxygen intermediates (22).  In the present work we tested individually many of 
2 C. F. Ockenhouse, S. Schulman, and H. L. Shear. Induction of crisis forms in the human malaria 
parasite,  Plasmodiura  falciparum,  by  gamma-interferon  activated,  monocyte-derived  macrophages. 
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the cytokines that affect macrophages, with special emphasis on non-'),  IFNs. Our 
findings are consistent with earlier studies in which all detectable MAF activity 
was depleted from  unfractionated,  polyclonally activated mononuclear cell  su- 
pernatants  by monoclonal  antibody to  IFN~,  (1,  2,  20).  Thus,  when  tested  in 
vitro in partially or highly purified form and over a wide range of concentrations, 
the following affected neither the antitoxoplasma activity of human macrophages 
nor,  with  one  exception,  their  secretion  of H~O2:  nIFNo~,  rIFNaA,  rIFNaD, 
rIFN/3, CSF-1, GM-CSF, p-CSF, MIF, niL-2, rIL-2, and TNF. 
MIF-rich  preparations  increased  macrophage  H202 secretion above control 
approximately threefold less than rIFNT.  It will be of interest to test the ability 
of MIF-treated macrophages to kill parasites more susceptible to oxidative injury 
than  toxoplasmas (22).  We have not yet studied  the effect of pure  MIF or of 
monoclonal  anti-MIF  antibodies,  and  thus  have  not proven  that  MIF was the 
active factor from the T-T hybridoma used here.  It also remains  to be seen if 
MAF is associated with  the  MIF produced by uncloned,  nontransformed  lym- 
phocytes. Further study of MIF is underway. 
Thus far, IFN~, appears to be the only known host-derived substance with the 
ability to activate both the oxidative metabolism and antitoxoplasma activity of 
human macrophages. 
Summary 
Cytokines affecting mononuclear phagocytes were screened for activation  of 
human macrophages to secrete H~O2 and kill toxoplasmas. In contrast to recom- 
binant  interferon-3,  (rIFN~),  the following factors, tested in partially or highly 
purified form and over a  wide range of concentrations,  did not augment these 
functions: native interferon-~ (nIFNa), rIFNaA, rIFNaD, rIFN/3, colony stimu- 
lating factor (type 1) (CSF-1), CSF for granulocytes and macrophages (GM-CSF), 
pluripotent CSF (p-CSF), tumor necrosis factor (TNF), native interleukin 2 (niL- 
2),  and  rIL-2.  Partially  purified  migration  inhibitory  factor  (MIF)  enhanced 
H202-releasing capacity submaximally without inducing antitoxoplasma activity, 
and warrants further study. 
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